OVERSEA CHINESE BANKING Corp Ltd Has $6.05 Million Holdings in Biogen Inc. $BIIB

OVERSEA CHINESE BANKING Corp Ltd lessened its stake in Biogen Inc. (NASDAQ:BIIB) by 25.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,366 shares of the biotechnology company’s stock after selling 11,837 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Biogen were worth $6,048,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Optas LLC boosted its holdings in shares of Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares during the period. Jones Kertz & Associates Inc. bought a new stake in shares of Biogen in the fourth quarter worth $790,000. Evergreen Capital Management LLC lifted its position in shares of Biogen by 11.7% in the fourth quarter. Evergreen Capital Management LLC now owns 2,588 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 271 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Biogen by 29.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 452,442 shares of the biotechnology company’s stock worth $79,625,000 after purchasing an additional 104,038 shares in the last quarter. Finally, Bayforest Capital Ltd lifted its position in shares of Biogen by 106.8% in the fourth quarter. Bayforest Capital Ltd now owns 887 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 458 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $185.95 on Wednesday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm’s fifty day moving average price is $185.55 and its two-hundred day moving average price is $174.62. Biogen Inc. has a 1 year low of $115.25 and a 1 year high of $202.41. The firm has a market capitalization of $27.29 billion, a P/E ratio of 21.11, a price-to-earnings-growth ratio of 2.46 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the firm posted $3.44 earnings per share. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts anticipate that Biogen Inc. will post 15.7 EPS for the current year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire exclusive Greater China rights to felzartamab (up to $850M), giving Biogen consolidated worldwide development and commercialization control of a CD38‑directed antibody currently in global Phase 3 trials — a meaningful commercial and strategic upside if late‑stage data and approvals succeed. Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
• Positive Sentiment: Wells Fargo upgraded BIIB to Overweight and boosted its price target to $250, a high‑profile bullish call that likely supported buying interest and helped lift the shares. Wells Fargo Upgrades Biogen to Overweight
• Neutral Sentiment: Coverage and media rundowns noted BIIB among names with large moves after the felzartamab news; these summaries amplify awareness but don’t add new fundamentals. Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen
• Neutral Sentiment: Recent earnings transcripts and previews (Q2 and Q3 filings/transcripts) reiterate management’s guidance and pipeline priorities but contained no surprise revisions that would immediately change the investment thesis. Biogen (BIIB) Q2 2025 Earnings Transcript Biogen (BIIB) Q3 2025 Earnings Transcript
• Negative Sentiment: HSBC reiterated a “Reduce” rating and set a $150 target while publishing mid‑cycle EPS estimates — a notable sell‑side headwind that provides a lower valuation anchor for skeptical investors. MarketBeat BIIB page (HSBC note referenced)
• Negative Sentiment: Opinion pieces arguing reasons to avoid BIIB highlight valuation and execution risks despite recent gains — these stories can temper momentum and attract short‑term profit‑taking. 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of a number of research reports. Tudor Pickering set a $201.00 price objective on shares of Biogen in a research report on Monday, February 9th. HSBC boosted their price objective on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday, March 17th. Morgan Stanley boosted their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. TD Cowen boosted their price objective on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Thirteen research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Biogen presently has a consensus rating of “Hold” and a consensus target price of $208.23.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.